Table 6.
Multivariable analyses of the predictors of self-reported and confirmed antimicrobial use
| Variable | Clinical model (N = 139) | Clinical model with IgA (N = 73) | Clinical model with IgG (N = 104) | Clinical model with IgM (N = 83) | ||||
|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | p value | OR (95% CI) | p value | OR (95% CI) | p value | OR (95% CI) | p value | |
| Age | 0.95 (0.91–1.00) | 0.048 | 0.85 (0.75–0.96) | 0.01 | 0.90 (0.84–0.97) | 0.004 | 0.87 (0.78–0.96) | 0.007 |
| Female gender | 1.82 (0.70–4.77) | 0.22 | 3.03 (0.32–2.83) | 0.33 | 1.27 (0.36–4.48) | 0.71 | 3.38 (0.50–22.82) | 0.21 |
| Disease duration | 1.02 (0.96–1.09) | 0.55 | 1.22 (1.06–1.41) | 0.006 | 1.10 (1.01–1.21) | 0.02 | 1.14 (1.02–1.28) | 0.02 |
| Number of ocrelizumab doses | 0.88 (0.64–1.22) | 0.44 | 0.58 (0.27–1.24) | 0.16 | 0.85 (0.54–1.35) | 0.49 | 0.76 (0.42–1.37) | 0.36 |
| EDSS | 1.21 (0.97–1.51) | 0.09 | 1.99 (1.02–3.86) | 0.04 | 1.34 (0.95–1.90) | 0.10 | 1.46 (0.92–2.31) | 0.10 |
| IgA level | 0.23 (0.07–0.79) | 0.02 | ||||||
| IgG level | 0.82 (0.65–1.04) | 0.11 | ||||||
| IgM level | 0.12 (0.10–1.50) | 0.13 | ||||||
Bold values indicate statistical significance
CI confidence intervals, EDSS Expanded Disability Status Scale, OR odds ratio